Antengene, K2 Therapeutics deal signals fresh momentum for solid tumor TCEs
Find out how Antengene’s ATG-106 licensing deal could shape the next phase of solid tumor T cell engager development.
Pharma & Biotech
Pharma & Biotech
Why OnCusp Therapeutics’ CFO hire matters for its CDH6 antibody-drug conjugate strategy
CDH6 ADCs are heating up. OnCusp Therapeutics now needs capital discipline to turn CUSP06 promise into clinical and investor credibility.